查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570932

吸入藥物市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Inhalable Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 117 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

吸入藥物市場到2023 年價值約為334 億美元，預計2024 年至2032 年間將以6.8% 的複合年成長率成長。到肺部），廣泛用於治療氣喘、慢性阻塞性肺病（COPD）、結核病（TB）和支氣管炎等呼吸系統疾病。它們的快速吸收和作用使其能夠非常有效地治療呼吸道疾病。

呼吸系統疾病的盛行率日益增加是市場成長的關鍵驅動力。隨著氣喘和慢性阻塞性肺病等疾病的發生率持續上升，對創新治療和預防措施的需求不斷成長。此外，吸入技術的進步和對呼吸系統疾病認知的提高正在推動市場擴張。

市面上依藥物劑型分為氣霧劑、乾粉劑及噴霧劑。乾粉製劑預計將大幅成長，到 2032 年將達到 218 億美元。 DPI 也易於使用、便攜，並且需要最少的給藥步驟，使其適合廣泛的患者，從而提高了其受歡迎程度和市場成長。

按應用，市場分為呼吸系統和非呼吸系統疾病。 2023年，呼吸系統疾病領域佔據市場主導地位，貢獻242億美元。吸入藥物直接向肺部提供標靶治療，減少全身副作用並更快產生治療效果。它們繞過消化系統的能力導致更快的吸收和更立即的反應，這對於管理急性呼吸道疾病至關重要。吸入藥物還需要比口服藥物更小的劑量，從而提高了其生物利用度和功效。

在分銷方面，市場分為醫院藥房、零售藥房和線上平台。到 2032 年，醫院藥房業務預計將達到 254 億美元。

在美國，在製藥創新、強大的醫療基礎設施以及研發 (R&D) 重大投資的推動下，吸入藥物市場預計到 2032 年將達到 218 億美元。美國在先進吸入式藥物輸送系統的開發方面處於領先地位，透過臨床試驗、監管批准和改善患者治療結果促進市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 呼吸道疾病盛行率增加
      • 吸入技術的進步
      • 提高認知和診斷
    • 產業陷阱與挑戰
      • 開發和生產成本高
      • 副作用和安全問題
  • 成長潛力分析
  • 監管環境
  • 技術景觀
    • 核心技術
    • 鄰近技術
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按藥物劑型，2021 - 2032 年

  • 主要趨勢
  • 氣霧劑
  • 乾粉配方
  • 噴

第 6 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 呼吸系統疾病
  • 非呼吸系統疾病

第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 8 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 9 章：公司簡介

  • AstraZeneca Plc
  • C.H. Boehringer Sohn AG and Co. KG.
  • CHIESI Farmaceutici S.p.A.
  • Cipla Limited
  • GSK plc
  • MannKind Corporation
  • Merck and Co., Inc.
  • Mundipharma International.
  • Novartis AG
  • Pfizer Inc.
  • PULMATRIX, INC.
  • Philip Morris International Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
簡介目錄
Product Code: 10744

The Inhalable Drugs Market, valued at approximately USD 33.4 billion in 2023, is expected to grow at a CAGR of 6.8% between 2024 and 2032. These drugs, delivered directly to the lungs through devices like inhalers, nebulizers, and dry powder inhalers (DPIs), are widely used for treating respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), tuberculosis (TB), and bronchitis. Their rapid absorption and action make them highly effective in addressing respiratory diseases.

The increasing prevalence of respiratory disorders is a key driver of market growth. As the incidence of conditions like asthma and COPD continues to rise, there is a growing demand for innovative treatments and preventive measures. Additionally, advancements in inhalation technology and greater awareness of respiratory conditions are fueling market expansion.

The market is segmented by drug form into aerosol, dry powder, and spray formulations. Dry powder formulations are projected to grow significantly, reaching USD 21.8 billion by 2032. These formulations offer stability due to the absence of liquid solvents or propellants, ensuring longer shelf life and reduced waste. DPIs are also easy to use, portable, and require minimal steps for administration, making them suitable for a wide range of patients, which enhances their popularity and market growth.

By application, the market is divided into respiratory and non-respiratory diseases. In 2023, the respiratory diseases segment dominated the market, contributing USD 24.2 billion. Inhalable drugs provide targeted treatment directly to the lungs, reducing systemic side effects and delivering quicker therapeutic results. Their ability to bypass the digestive system leads to faster absorption and a more immediate response, which is crucial for managing acute respiratory conditions. Inhalable drugs also require smaller doses than oral medications, increasing their bioavailability and efficacy.

Regarding distribution, the market is segmented into hospital pharmacies, retail pharmacies, and online platforms. The hospital pharmacies segment is anticipated to reach USD 25.4 billion by 2032. These pharmacies specialize in the compounding and formulation of inhalable drugs, ensuring precise dosing and high-quality standards for safe and effective treatment.

In the U.S., the inhalable drugs market is expected to reach USD 21.8 billion by 2032, driven by pharmaceutical innovation, robust healthcare infrastructure, and significant investments in research and development (R&D). The U.S. leads in the development of advanced inhalable drug delivery systems, fostering market growth through clinical trials, regulatory approvals, and enhanced patient outcomes.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of respiratory diseases
      • 3.2.1.2 Advancements in inhalation technology
      • 3.2.1.3 Growing awareness and diagnosis
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High development and production costs
      • 3.2.2.2 Side effects and safety concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Form, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Aerosol
  • 5.3 Dry powder formulation
  • 5.4 Spray

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Respiratory diseases
  • 6.3 Non-respiratory diseases

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacies
  • 7.3 Retail pharmacies
  • 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 AstraZeneca Plc
  • 9.2 C.H. Boehringer Sohn AG and Co. KG.
  • 9.3 CHIESI Farmaceutici S.p.A.
  • 9.4 Cipla Limited
  • 9.5 GSK plc
  • 9.6 MannKind Corporation
  • 9.7 Merck and Co., Inc.
  • 9.8 Mundipharma International.
  • 9.9 Novartis AG
  • 9.10 Pfizer Inc.
  • 9.11 PULMATRIX, INC.
  • 9.12 Philip Morris International Inc.
  • 9.13 Sanofi
  • 9.14 Teva Pharmaceutical Industries Ltd.
  • 9.15 Viatris Inc.